Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02041273 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability Of Palbociclib (PD-0332991) Under Fed And Fasted Conditions
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT02041273 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 36 participants.
The verdict
NCT02041273, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
A relative bioavailability study of commercial palbociclib free base hard capsules to the isethionate salt palbociclib capsules ( used in Phase 1 and 2 studies) under different fasting conditions.
Interventions
- DRUG palbociclib isethionate (phase 1 and 2 studies)
- DRUG palbociclib commercial free base capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02041273
The ClinicalTrials.gov registry entry for NCT02041273 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which palbociclib isethionate (phase 1 and 2 studies) is the first listed.
NCT02041273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02041273 about?
NCT02041273 is a clinical study titled "Relative Bioavailability Of Palbociclib (PD-0332991) Under Fed And Fasted Conditions". A relative bioavailability study of commercial palbociclib free base hard capsules to the isethionate salt palbociclib capsules ( used in Phase 1 and 2 studies) under different fasting conditions.
What is the current status of trial NCT02041273?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2014-01. Estimated completion is 2014-03.
What interventions are being tested in trial NCT02041273?
The interventions under investigation include: palbociclib isethionate (phase 1 and 2 studies) (DRUG), palbociclib commercial free base capsule (DRUG).
Who is sponsoring clinical trial NCT02041273?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.